For an enlarged prostate, two drug classes work — and combining them works better

For a man whose enlarged prostate is making it hard to urinate, the evidence best supports two classes of drug: alpha-blockers, which relax the muscle at the bladder outlet and relieve symptoms within days to weeks, and 5-alpha-reductase inhibitors, which slowly shrink the gland over months [s1][s3]. In the largest long-term trial, combining the two cut the risk of the condition worsening by 66% against placebo, more than either drug alone [s1]; for men who want to avoid or postpone drugs, newer office-based procedures such as water-vapour ablation improve symptoms while preserving erectile and ejaculatory function [s5][s4].

What the condition is — and is not

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate that squeezes the urethra and produces lower urinary tract symptoms: a weak stream, hesitancy, incomplete emptying, and waking at night to urinate. It is not prostate cancer, and drug treatment for BPH does not treat cancer; the two are assessed differently, which is part of why the PSA blood test is such a blunt instrument. The American Urological Association's guideline frames initial care around symptom severity and how much the symptoms bother the man, working up from lifestyle measures to medication to procedures [s3][s4].

The two drug classes, and the case for combining them

The pivotal evidence comes from the Medical Therapy of Prostatic Symptoms (MTOPS) trial, a double-blind study of 3,047 men followed for a mean of 4.5 years [s1]. Compared with placebo, the alpha-blocker doxazosin reduced the risk of overall clinical progression — defined as a rise of at least 4 points in the AUA symptom score, acute urinary retention, incontinence, renal insufficiency, or recurrent urinary infection — by 39%, and the 5-alpha-reductase inhibitor finasteride reduced it by 34% [s1]. Combination therapy reduced that risk by 66%, significantly more than either drug on its own [s1].

The two classes do different jobs, which is why they add up. Alpha-blockers act fast on symptoms but do not change the gland; 5-alpha-reductase inhibitors shrink the prostate and, in MTOPS, were the component that lowered the longer-term risks of acute urinary retention and of needing surgery — reductions that doxazosin alone did not deliver [s1].

The CombAT study extended the logic to a higher-risk group: 4,844 men aged 50 or older with a prostate volume of at least 30 cm³, a symptom score of 12 or more, and a PSA of 1.5 to 10 ng/mL, randomised to tamsulosin 0.4 mg, dutasteride 0.5 mg, or both for four years [s2]. Combination therapy beat tamsulosin monotherapy at reducing the risk of acute retention or BPH-related surgery, beat both monotherapies at slowing clinical progression, and gave greater symptom relief than either alone [s2].

The trade-offs are real

Combining drugs means combining side effects, and the evidence does not hide them. In CombAT the safety profile matched what was already known for each drug, with one exception the authors flagged: an imbalance in reports of cardiac failure across the three arms [s2]. The 5-alpha-reductase inhibitors carry their own well-documented sexual side effects — the same drugs, at lower doses, are used for male-pattern hair loss, where those harms are debated. None of this makes the drugs a poor choice; it makes them a choice that turns on how severe a man's symptoms are and how much they bother him, which is exactly how the guideline frames the decision [s3].

The newer procedures

For men who want durable relief without daily pills — or who cannot tolerate them — minimally invasive procedures now sit between drugs and traditional surgery. In a randomised, controlled trial of 197 men (136 treated, 61 control, allocated 2:1), convective water-vapour thermal therapy (marketed as Rezūm) reduced the International Prostate Symptom Score by 11.2 points versus 4.3 in the control group at three months [s5]. Treated men started at an average score of 22 and saw it fall by 50% or more at 3, 6 and 12 months, with peak urinary flow rising by 6.2 mL per second and no cases of new erectile dysfunction reported [s5]. Preserving sexual function is the selling point: standard surgery for BPH commonly causes retrograde ejaculation, and water-vapour therapy was designed to avoid it [s5].

The AUA's surgical guideline catalogues two dozen distinct statements covering everything from these office procedures to full operative approaches, matched to prostate size and patient characteristics [s4]. The point is that there is no single "prostate operation" any more — the menu ranges from a vapour injection under local anaesthetic to major resection.

What it means

An enlarged prostate is common with age and is not, in itself, dangerous; the reason to treat it is symptoms and their complications, not the size of the gland. The strongest evidence supports starting with an alpha-blocker for quick relief, adding or switching to a 5-alpha-reductase inhibitor when the gland is enlarged and progression is the worry, and combining them when both aims matter [s1][s2]. Procedures are no longer a last resort, and the ones that preserve sexual function have real randomised evidence behind their symptom benefit [s5]. What is worth watching is that none of this bears on prostate cancer — BPH symptoms and an elevated PSA send a man down different diagnostic paths, and conflating them is a common and costly error.

Sources

• [s1] New England Journal of Medicine — The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia (MTOPS) (2003-12-18)
• [s2] European Urology — The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic BPH: 4-Year Results from the CombAT Study (2009-09-20)
• [s3] Journal of Urology (AUA) — Management of LUTS Attributed to BPH: AUA Guideline Part I — Initial Work-up and Medical Management (2021-08-13)
• [s4] Journal of Urology (AUA) — Management of LUTS Attributed to BPH: AUA Guideline Part II — Surgical Evaluation and Treatment (2021-08-13)
• [s5] Journal of Urology — Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study (2015-11-22)